Patent ID: 11957683
Assignee: ALIGOS THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, having the structure:, wherein:
n is 0 or 1;
Z1 is —C(═O)—or —NH—C(═O)—;
R1 is selected from the group consisting of an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted aryl(C1-4 alkyl), an optionally substituted heteroaryl(C1-4 alkyl) and an optionally substituted heterocyclyl(C1-4 alkyl);
R2 and R3 are independently selected from the group consisting of hydrogen, an optionally substituted C1-4 alkyl, an optionally substituted C2-4 alkenyl, an optionally substituted C2-4 alkynyl, an unsubstituted C1-4 haloalkyl, an optionally substituted monocyclic C3-6 cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted aryl(C1-4 alkyl), an optionally substituted heteroaryl(C1-4 alkyl) and an optionally substituted heterocyclyl(C1-4 alkyl);
R4 and R5 are independently selected from the group consisting of hydrogen, an unsubstituted C1-4 alkyl, an unsubstituted C1-4 haloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted aryl(C1-4 alkyl), an optionally substituted heteroaryl(C1-4 alkyl) and an optionally substituted heterocyclyl(C1-4 alkyl);
R6 and R7 are independently selected from the group consisting of hydrogen, an unsubstituted C1-4 alkyl and an unsubstituted C1-4 haloalkyl;
R8 is —NR10AR10B or an optionally substituted C2-12 alkynyl, wherein the C2-12 alkynyl is optionally substituted with one or more substituents selected from the group consisting of amino, —NH—C(═O)(an unsubstituted C1-4 alkyl), hydroxy, an unsubstituted C1-4 alkoxy, an unsubstituted C1-4 haloalkyl, an unsubstituted C3-4 monocyclic cycloalkyl, a fluoro-substituted C3-4 monocyclic cycloalkyl, a hydroxy-substituted C3-4 monocyclic cycloalkyl an unsubstituted 4-6 membered monocyclic heterocyclyl, an optionally substituted aryl and an optionally substituted 5-6 membered monocyclic heteroaryl;
R9 is a substituted phenyl, a substituted monocyclic heteroaryl or a substituted fused-bicyclic heteroaryl, wherein the substituted phenyl, the substituted monocyclic heteroaryl or the substituted fused-bicyclic heteroaryl is substituted with one or more substituents selected from the group consisting of halogen, an unsubstituted C1-4 alkyl, a cyano-substituted C1-4 alkyl, an unsubstituted C1-4 haloalkyl, an unsubstituted C1-4 alkoxy, a hydroxy-substituted C1-4 alkoxy, an optionally substituted monocyclic C3-6 cycloalkyl, an optionally substituted monocyclic heteroaryl, an optionally substituted monocyclic heterocyclyl, amino, a mono-substituted amine, a di-substituted amine and —C(═O)NHR11;
R10A is hydrogen, an unsubstituted C1-6 alkyl, a monocyclic C3-6 cycloalkyl optionally substituted with one or two halogens, an optionally substituted 5-6 membered monocyclic heteroaryl, an optionally substituted 4-6 membered monocyclic heterocyclyl or an optionally substituted monocyclic C3-6 cycloalkyl(C1-4 alkyl);
R10B is an optionally substituted C2-8 alkenyl, wherein the C2-8 alkenyl is optionally substituted with one or more substituents selected from the group consisting of amino, hydroxy, an unsubstituted C1-4 alkoxy, an unsubstituted C1-4 haloalkyl, an unsubstituted C3-4 monocyclic cycloalkyl, a fluoro-substituted C3-4 monocyclic cycloalkyl, a hydroxy-substituted C3-4 monocyclic cycloalkyl and an unsubstituted 4-6 membered monocyclic heterocyclyl;
wherein when R10A is an optionally substituted monocyclic C3-6 cycloalkyl(C1-4 alkyl), then R10B cannot be an unsubstituted C2-6 alkenyl; and
R11 is hydrogen, an unsubstituted C1-6 alkyl, an optionally substituted C2-6 alkenyl, an optionally substituted C1-6 alkynyl or an optionally substituted C3-6 monocyclic cycloalkyl.